We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$325M
AUM Growth
+$325M
Cap. Flow
+$154M
Cap. Flow %
47.4%
Top 10 Hldgs %
48.17%
Holding
91
New
22
Increased
30
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$9.77M
2
VCYT icon
Veracyte
VCYT
+$5.92M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$3.98M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.72M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.45M
3
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$1.55M
4
IMGN
Immunogen Inc
IMGN
+$993K
5
IMTX icon
Immatics
IMTX
+$714K

Sector Composition

Rank Sector Weight
1 Healthcare 64.89%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
51
Seres Therapeutics
MCRB
$46.5M
$1.19M 0.37%
17,388
+1,044
+6% +$89.9K
NGM
52
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.13M 0.35%
88,303
-112,191
-56% -$1.55M
ZYME icon
53
Zymeworks
ZYME
$1.66B
$1.1M 0.34%
+208,330
New +$1.26M
PSTX
54
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$982K 0.3%
380,606
+140,910
+59% +$392K
CLDX icon
55
Celldex Therapeutics
CLDX
$2.79B
$979K 0.3%
36,322
-9,216
-20% -$268K
CLDX icon
56
PUT
Celldex Therapeutics
CLDX
$2.79B
$971K 0.3%
+36,000
New +$1.05M
SPRY icon
57
ARS Pharmaceuticals
SPRY
$563M
$887K 0.27%
+209,108
New +$729K
PYPD icon
58
PolyPid
PYPD
$71.9M
$750K 0.23%
5,386
-1,887
-26% -$282K
STXS icon
59
Stereotaxis
STXS
$128M
$678K 0.21%
368,648
+22,243
+6% +$53.2K
FMTX
60
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$650K 0.2%
94,386
-80,382
-46% -$564K
CCXI
61
DELISTED
ChemoCentryx, Inc.
CCXI
$645K 0.2%
+26,036
New +$574K
BCRX icon
62
BioCryst Pharmaceuticals
BCRX
$2.48B
$566K 0.17%
53,521
-48,904
-48% -$504K
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.09B
$394K 0.12%
+52,066
New +$505K
ELOX
64
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$281K 0.09%
26,037
-22,737
-47% -$314K
CGEN icon
65
Compugen
CGEN
$214M
$193K 0.06%
104,150
-164,446
-61% -$355K
MREO
66
Mereo BioPharma
MREO
$49.4M
$175K 0.05%
156,195
-79,320
-34% -$61.5K
EVGN icon
67
Evogene
EVGN
$5.99M
$156K 0.05%
20,232
-9,343
-32% -$91.3K
ALGS icon
68
Aligos Therapeutics
ALGS
$26.3M
$71K 0.02%
2,336
+1,910
+448% +$64.9K
MSACW
69
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$9K ﹤0.01%
49,990
– –
RCOR.WS
70
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$6K ﹤0.01%
104,828
– –
AMLX icon
71
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-30,000
Closed -$386
ASND icon
72
Ascendis Pharma A/S
ASND
$16.7B
– –
-25,000
Closed -$1.43K
LONA
73
LeonaBio Inc
LONA
$65.5M
– –
-1,000
Closed -$27K
BNTC icon
74
Benitec Biopharma
BNTC
$408M
– –
-28,993
Closed -$57
BGMS
75
Bio Green Med Solution Inc
BGMS
$4.94M
– –
-129
Closed -$1.41K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Silverarc Capital Management held 91 positions worth $325M, up 134,306% from $242K the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $154M of net new capital in Q2 2022, opening 22 new positions and adding to 30 existing holdings. Its largest new stake was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.72M trimmed.

  • Silverarc Capital Management's largest Q2 2022 buy was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q2 2022, an estimated $9.77M increase.
  • Silverarc Capital Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $9.72M.
  • Silverarc Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $27K.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $325M portfolio in Q2 2022.
  • Silverarc Capital Management opened 22 new positions and closed 21 in Q2 2022.
  • Silverarc Capital Management's portfolio value rose 134,306% quarter-over-quarter to $325M.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.